Growing Capital Base Hadean Ventures recently closed its latest fund, Hadean Capital II, securing €144 million in funding, indicating strong financial capacity and a readiness to invest in innovative life science companies across Europe.

Active Investment Strategy With recent investments in companies like Alex Therapeutics, TargED Biopharmaceuticals, and Ribbon Biolabs, Hadean Ventures shows a continuous focus on funding cutting-edge biotech, digital health, and medtech startups, presenting opportunities for relevant technology providers.

Nordic Leadership Based in Oslo and Stockholm and focused on the Nordic and broader European markets, Hadean Ventures offers a gateway for companies in life sciences to access European venture capital and expand their operational reach.

SME Market Focus With a relatively modest revenue range of $1M to $10M, Hadean Ventures primarily supports early to mid-stage companies, providing a potential market for service providers specializing in scaling biotech and medtech startups.

Industry Engagement Hadean Ventures’ engagement in financing biotech, diagnostics, and digital therapeutics signals opportunities for partnerships in clinical development, regulatory consulting, and innovative medical technologies to support their portfolio growth.